Lenvatinib, an FDA-approved anti-cancer small chemical inhibitor of multiple tyrosine kinases, induced AZGP1 expression in cholangiocarcinoma where it led to the suppression of TGF-β1-induced EMT [306]. Here, AZGP1 is linked to cancer.